GRAFT VS HOST DISEASE
Clinical trials for GRAFT VS HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new GRAFT VS HOST DISEASE trials appear
Sign up with your email to follow new studies for GRAFT VS HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Aggressive chemo plus stem cell transplant tested for breast cancer
Disease control CompletedThis completed Phase 2 trial tested whether high-dose chemotherapy followed by a stem cell transplant could help people with breast cancer that responds to standard chemo. 203 patients with stage II, III, or IV breast cancer took part. The main goal was to see how long they survi…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug shows promise in preventing Graft-Versus-Host disease
Disease control CompletedThis early study tested the drug belimumab (Benlysta) to see if it could prevent chronic graft-versus-host disease (GvHD) in 10 adults who had a stem cell transplant for blood cancer. GvHD is a serious condition where the donor's immune cells attack the patient's body. The main g…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control CompletedThis study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's …
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Liver transplant study tests Lower-Dose immune drugs to prevent deadly Graft-Versus-Host disease
Disease control CompletedThis study looked at 100 liver transplant patients to see if using less immune-suppressing medication could lower the risk of graft-versus-host disease (GVHD), a serious condition where donor cells attack the recipient's body. Researchers tracked how many patients developed GVHD …
Matched conditions: GRAFT VS HOST DISEASE
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise for kids with transplant complication
Disease control CompletedThis study tested whether adding the drug ruxolitinib to standard steroids helps children with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. 46 children aged 28 days to 18 years took part. The main goal was to see how many had a complete o…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo shows promise in preventing deadly transplant complication
Disease control CompletedThis study tested whether adding the drug abatacept to standard medications (calcineurin inhibitor and methotrexate) could better prevent severe acute graft-versus-host disease (aGVHD) after a stem cell transplant from an unrelated donor. A total of 186 participants aged 6 and ol…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for tough GvHD: pomalidomide shows promise in small trial
Disease control CompletedThis study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD) that didn't improve with standard treatments. GvHD can happen after a stem cell transplant when the donor cells attack the recipient's body. Participants took pomalidomide caps…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug shows promise in preventing transplant complication
Prevention CompletedThis study tested whether the drug obinutuzumab can prevent chronic graft-versus-host disease (cGVHD), a common and serious complication after a stem cell transplant. 181 people who had a stem cell transplant took part. The goal was to see if obinutuzumab could reduce the need fo…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC